This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective, randomised, open-label, clinical trial that was carried out at several centres in the UK. Randomisation was performed by telephone and was stratified by referring GP. At recruitment, patients were informed that, if they or their doctor preferred, an alternative treatment could be prescribed from a different class to that allocated at random. Of the 327 participants, 92 patients were finally prescribed a different class of antidepressant. Doctors prescribed using UK recommended dosages and continued treatment for 6 months after remission of the depressive episode, or for at least 12 months if the patient had experienced two or more depressive episodes within the past 5 years. Therefore, the length of follow-up was 12 months. Full data on the outcome measures were available for 254 patients at 3 months (78%), 203 (62%) at 6 months, 188 (58%) at 9 months and 171 (52%) at 12 months, with no significant difference in completeness between the groups. The authors stated that blinding was not performed as it was impossible to mask researchers to group allocation.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. All outcome measures were selfcompleted. The primary clinical measure was the number of weeks free from depression, defined as a score of below 8 on the Hospital Anxiety and Depression Scale -Depression sub-scale (HADS-D). Other clinical outcomes were measures of psychiatric symptoms, such as the Clinical Interview Schedule -Revised (CIS-R), a measure of general health status (the 36-item Medical Outcomes Study Short Form, SF-36), and quality of life (EuroQol EQ-5D questionnaire). Linear interpolation of missing values was performed. Differences in the number of weeks free from depression were adjusted by baseline HADS-D scores. A multilevel generalised model was used to adjust for differences in baseline EQ-5D scores. The baseline comparability of the study groups was not explicitly discussed, but it is likely that there were no differences in the patients' characteristics given the randomisation process.
Effectiveness results
The proportions of patients who were prescribed a different class of drug differed significantly between allocated classes: 42% for TCAs, 27% for LOF and 16% for SSRIs, (p=0.001).
No statistically significant differences between the groups were observed in any outcome measure. For example, the numbers of depression-free weeks over 12 months were 25.3 (95% confidence interval, CI: 21.3 to 29.0) for TCAs, 28.3 (95% CI: 24.3 to 32.2) for SSRIs and 24.6 (95% CI: 20.6 to 28.9) for LOF, (p=0.327).
Clinical conclusions
The effectiveness analysis showed that the three treatments were equally effective.
Measure of benefits used in the economic analysis
The summary benefit measures were the number of disease-free weeks and quality-adjusted life-years (QALYs). The number of disease-free weeks was obtained directly from the effectiveness analysis. The QALYs were estimated by
